Hye Sook Chon

5.2k total citations
68 papers, 680 citations indexed

About

Hye Sook Chon is a scholar working on Reproductive Medicine, Oncology and Obstetrics and Gynecology. According to data from OpenAlex, Hye Sook Chon has authored 68 papers receiving a total of 680 indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Reproductive Medicine, 26 papers in Oncology and 24 papers in Obstetrics and Gynecology. Recurrent topics in Hye Sook Chon's work include Ovarian cancer diagnosis and treatment (33 papers), Endometrial and Cervical Cancer Treatments (23 papers) and PARP inhibition in cancer therapy (10 papers). Hye Sook Chon is often cited by papers focused on Ovarian cancer diagnosis and treatment (33 papers), Endometrial and Cervical Cancer Treatments (23 papers) and PARP inhibition in cancer therapy (10 papers). Hye Sook Chon collaborates with scholars based in United States, Spain and Belgium. Hye Sook Chon's co-authors include Robert M. Wenham, Johnathan M. Lancaster, Sachin M. Apte, John J. Kavanagh, Wei Hu, Kathleen N. Moore, Yin Xiong, Leslie M. Randall, Jesús González Bosquet and Alexander L. Vahrmeijer and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and American Journal of Obstetrics and Gynecology.

In The Last Decade

Hye Sook Chon

59 papers receiving 666 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hye Sook Chon United States	16	222	213	211	135	119	68	680
Antonella Pietragalla Italy	17	270 1.2×	262 1.2×	210 1.0×	154 1.1×	119 1.0×	36	693
Shelly Seward United States	15	390 1.8×	298 1.4×	246 1.2×	121 0.9×	157 1.3×	34	898
M. Amneus United States	10	139 0.6×	354 1.7×	273 1.3×	125 0.9×	245 2.1×	18	854
Shu Soeda Japan	14	205 0.9×	144 0.7×	163 0.8×	180 1.3×	106 0.9×	67	702
Chiao‐Yun Lin Taiwan	18	151 0.7×	410 1.9×	124 0.6×	106 0.8×	146 1.2×	71	822
Satoshi Tsunetoh Japan	15	243 1.1×	280 1.3×	235 1.1×	188 1.4×	159 1.3×	32	715
Huimin Bai China	17	263 1.2×	326 1.5×	341 1.6×	272 2.0×	118 1.0×	52	907
Yoshimichi Tanaka Japan	16	269 1.2×	350 1.6×	280 1.3×	198 1.5×	194 1.6×	45	850
Marilena Di Napoli Italy	16	433 2.0×	331 1.6×	374 1.8×	210 1.6×	187 1.6×	64	1.0k
Denise Uyar United States	16	252 1.1×	257 1.2×	229 1.1×	138 1.0×	126 1.1×	43	664

Countries citing papers authored by Hye Sook Chon

Since Specialization

Citations

This map shows the geographic impact of Hye Sook Chon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hye Sook Chon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hye Sook Chon more than expected).

Fields of papers citing papers by Hye Sook Chon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hye Sook Chon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hye Sook Chon. The network helps show where Hye Sook Chon may publish in the future.

Co-authorship network of co-authors of Hye Sook Chon

This figure shows the co-authorship network connecting the top 25 collaborators of Hye Sook Chon. A scholar is included among the top collaborators of Hye Sook Chon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hye Sook Chon. Hye Sook Chon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Westin, Shannon N., Kathleen N. Moore, Hye Sook Chon, et al.. (2025). Durvalumab Plus Carboplatin/Paclitaxel Followed By Durvalumab With/Without Olaparib In Endometrial Cancer: Exploratory Analyses Of Histology, Biomarker Heterogeneity And Efficacy In The DUO-E Mismatch Repair Proficient Subpopulation. International Journal of Gynecological Cancer. 35(2). 101703–101703.

Moore, Kathleen N., Shannon N. Westin, Hye Sook Chon, et al.. (2025). Durvalumab plus carboplatin/paclitaxel followed by durvalumab with/without olaparib in endometrial cancer: Biomarkers, histological heterogeneity, baseline circulating tumor DNA and efficacy in the DUO-E mismatch repair proficient subpopulation. Gynecologic Oncology. 200. 345–346. 1 indexed citations

Chon, Hye Sook, Michael J. Sundborg, Michael S. Gold, et al.. (2024). Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for endometrial cancer (DUO-E/GOG-3041/ENGOT-EN10): Objective response rate and duration of response by mismatch repair status. Gynecologic Oncology. 190. S61–S62. 2 indexed citations

Fidalgo, José Alejandro Pérez, Ignace Vergote, Erika Hamilton, et al.. (2024). PO003/#1168 Longer-term safety and efficacy of selinexor maintenance therapy for patients with TP53WT advanced or recurrent endometrial cancer: follow up subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study. A16–A17. 1 indexed citations

Baurain, Jean‐François, Hye Sook Chon, Michael J. Sundborg, et al.. (2024). Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as a firstline treatment for endometrial cancer: Overall survival and additional secondary efficacy en‑dpoints by mismatch repair status in the DUO-E/GOG-3041/ENGOT-EN10 Trial. Gynecologic Oncology. 190. S62–S63.

Banerjee, Susana, Carol Aghajanian, Els Van Nieuwenhuysen, et al.. (2024). LB007/#1548 Efficacy and safety of avutometinib ± defactinib in recurrent low grade serous ovarian cancer: primary analysis of ENGOT-OV60/GOG-3052/RAMP 201. A13–A13. 1 indexed citations

Tanyi, János L., Leslie M. Randall, Setsuko K. Chambers, et al.. (2023). A Phase III Study of Pafolacianine Injection (OTL38) for Intraoperative Imaging of Folate Receptor–Positive Ovarian Cancer (Study 006). Obstetrical & Gynecological Survey. 78(6). 341–342.

Westin, Shannon N., Kathleen N. Moore, Hye Sook Chon, et al.. (2023). LBA41 Durvalumab (durva) plus carboplatin/paclitaxel (CP) followed by maintenance (mtx) durva ± olaparib (ola) as a first-line (1L) treatment for newly diagnosed advanced or recurrent endometrial cancer (EC): Results from the phase III DUO-E/GOG-3041/ENGOT-EN10 trial. Annals of Oncology. 34. S1282–S1283. 7 indexed citations

Oswald, Laura B., Danielle B. Tometich, Aasha I. Hoogland, et al.. (2022). Cumulative burden of symptomatology in patients with gynecologic malignancies undergoing chemotherapy.. Health Psychology. 41(11). 864–873. 5 indexed citations

10.

Martin, Alexandra, Sweta Sinha, Lauren C. Peres, et al.. (2022). The impact of distance to closest negative margin on survival after pelvic exenteration. Gynecologic Oncology. 165(3). 514–521. 6 indexed citations

11.

Kunos, Charles A., Stephen Andrews, Kathleen N. Moore, Hye Sook Chon, & S. Percy Ivy. (2019). Randomized Phase II Trial of Triapine-Cisplatin-Radiotherapy for Locally Advanced Stage Uterine Cervix or Vaginal Cancers. Frontiers in Oncology. 9. 1067–1067. 43 indexed citations

12.

Mohammadi, Homan, Nicholas Figura, Jeffrey Peacock, et al.. (2019). Using the Radiosensitivity Index (RSI) to Predict Pelvic Failure in Endometrial Cancer Treated With Adjuvant Radiation Therapy. International Journal of Radiation Oncology*Biology*Physics. 106(3). 496–502. 26 indexed citations

13.

Rishi, Anupam, Kamran A. Ahmed, Dylan Hunt, et al.. (2019). High-dose intensity-modulated chemoradiotherapy in vulvar squamous cell carcinoma: Outcome and toxicity. Gynecologic Oncology. 156(2). 349–356. 19 indexed citations

14.

Ahmed, Kamran A., Young‐Chul Kim, Sachin M. Apte, et al.. (2019). Trial in progress: Phase II study of stereotactic body radiation therapy and atezolizumab in the management of recurrent, persistent, or metastatic cervical cancer.. Journal of Clinical Oncology. 37(15_suppl). TPS5596–TPS5596. 2 indexed citations

15.

Chon, Hye Sook, Sokbom Kang, Jae K. Lee, et al.. (2017). Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers. BMC Cancer. 17(1). 407–407. 11 indexed citations

16.

Xiong, Yin, Douglas C. Marchion, Forough Abbasi, et al.. (2015). Micro-RNAs associated with the evolution of ovarian cancer cisplatin resistance. Gynecologic Oncology. 140(2). 259–263. 16 indexed citations

17.

Judson, Patricia L., Douglas C. Marchion, Yin Xiong, et al.. (2012). Characterizing the Efficacy of Fermented Wheat Germ Extract Against Ovarian Cancer and Defining the Genomic Basis of Its Activity. International Journal of Gynecological Cancer. 22(6). 960–967. 18 indexed citations

18.

Chon, Hye Sook, William D. Bush, Chang Won Kang, & Mitchel S. Hoffman. (2012). Robotic-assisted resection of isolated paraaortic lymph node recurrence with right lateral decubitus position. Journal of Robotic Surgery. 7(2). 205–207. 1 indexed citations

19.

Xia, Tao, Hye Sook Chon, Siqing Fu, John J. Kavanagh, & Wei Hu. (2008). Update on Aurora Kinase Inhibitors in Gynecologic Malignancies. Recent Patents on Anti-Cancer Drug Discovery. 3(3). 162–177. 5 indexed citations

20.

Chon, Hye Sook, Wei Hu, & John J. Kavanagh. (2006). Targeted Therapies in Gynecologic Cancers. Current Cancer Drug Targets. 6(4). 333–363. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact